Skip to Main Content

Author Details

Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
2012
76
21
PMIDPaper TitleJournal TitlePublished Year
35318568Racial disparities in follow-up care of early-stage lung cancer survivors.J Cancer Surviv2023
37324070Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy.J Thorac Dis2023
37373756Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.J Clin Med2023
37036756A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.Oncotarget2023
36441447Oncolytic Viruses and Cancer Immunotherapy.Curr Oncol Rep2023
36675528A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.J Clin Med2023
36702816Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.Cell Death Dis2023
34669023A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.Cancer Chemother Pharmacol2022
35732569Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.Mol Cancer Ther2022
35399566The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating <i>MYC</i>-target genes.Transl Lung Cancer Res2022
35396812A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).Cancer Med2022
35813711Clinical outcomes and immune phenotypes associated with <i>STK11</i> co-occurring mutations in non-small cell lung cancer.J Thorac Dis2022
35780243A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.Eur J Med Res2022
36233569Addressing Drug Resistance in Cancer: A Team Medicine Approach.J Clin Med2022
36387729Smoothened percentiles for height, weight and body mass index of urban school going adolescents aged 11-17 years in national capital territory region of Delhi, India.J Family Med Prim Care2022
33577360Montelukast in hospitalized patients diagnosed with COVID-19.J Asthma2022
34953399Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.ESMO Open2022
34978902Oral Care: Focused History and Examination in Patients with Serious Illness #430.J Palliat Med2022
33376097Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903).Clin Cancer Res2021
33718010Comprehensive genomic profiling of combined small cell lung cancer.Transl Lung Cancer Res2021
33521559Combining radiation therapy and immunotherapy for lung cancers: a narrative review.Shanghai Chest2021
33652156A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.J Thorac Oncol2021
33889521Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development.Transl Lung Cancer Res2021
35004237Use of tumor cell lysate to develop peptide vaccine targeting cancer-testis antigens.Transl Lung Cancer Res2021
34590018Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504).JTO Clin Res Rep2021
34263627Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer.Ann Palliat Med2021
33407808The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy.Acta Neuropathol Commun2021
32298223Racial Disparities in Health Care Utilization at the End of Life Among New Jersey Medicaid Beneficiaries With Advanced Cancer.JCO Oncol Pract2020
32077891Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.JAMA Oncol2020
33282413Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)-current consensus and future perspectives.J Thorac Dis2020
33166854Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.Cancer Treat Res Commun2020
32761104Assessing Expression of PD-L1 in Tumor-Associated Macrophages-Reply.JAMA Oncol2020
32642155Tumor volume reduction evaluated by cone beam computed tomography during stereotactic body radiotherapy for early stage non-small cell lung cancer.J Thorac Dis2020
33020239Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.J Immunother Cancer2020
31019945Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer.Ann Transl Med2019
31747591Non-Genetic Intra-Tumor Heterogeneity Is a Major Predictor of Phenotypic Heterogeneity and Ongoing Evolutionary Dynamics in Lung Tumors.Cell Rep2019
32038912Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors.Transl Lung Cancer Res2019
30144583Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy.Pract Radiat Oncol2019
31360811Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution.Adv Radiat Oncol2019
31463691A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.Cancer Chemother Pharmacol2019
31521049Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).Cancer Treat Res Commun2019
31118108Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.J Immunother Cancer2019
27322697Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.Am J Clin Oncol2018
29935771Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy.Bioorg Med Chem Lett2018
29883836Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC.J Thorac Oncol2018
30123560ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?J Thorac Dis2018
30206493Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy.J Thorac Dis2018
30429021Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer.Lung Cancer2018
30631567Examining EML4-ALK variants in the clinical setting: the next frontier?J Thorac Dis2018
29730063Daily Image Guidance With Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys2018
  • 1 - 50 of 76

Recommended Authors

the First Affiliated Hospital of Guangzhou Medical University
Career Start Year 2013
Number of shared co-authors 0
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 2
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 2
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 1
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 1
Yonsei Cancer Center, Yonsei University College of Medicine
Career Start Year 2005
Number of shared co-authors 2
David Geffen School of Medicine, University of California Los Angeles
Career Start Year 2005
Number of shared co-authors 2
The Ottawa Hospital Research Institute
Career Start Year 2005
Number of shared co-authors 1
University of California san francisco
Career Start Year 2003
Number of shared co-authors 1
The First People's Hospital of Zhaoqing
Career Start Year 2003
Number of shared co-authors 0
Jonsson Comprehensive Cancer Center, university of california los angeles
Career Start Year 2002
Number of shared co-authors 0
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 6
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 3
The University of Manchester
Career Start Year 2000
Number of shared co-authors 2
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 0
Mayo Clinic
Career Start Year 1996
Number of shared co-authors 18
UT Southwestern Medical Center, Center for Human Nutrition
Career Start Year 1996
Number of shared co-authors 0
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 0
University of British Columbia
Career Start Year 1995
Number of shared co-authors 1
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 1
The Princess Margaret Cancer Centre/University of Toronto
Career Start Year 1992
Number of shared co-authors 21
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 3
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 16
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 4
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 3
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 2
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 4
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Career Start Year 1978
Number of shared co-authors 4
University Health Network, Princess Margaret Cancer Centre
Career Start Year 1977
Number of shared co-authors 17

Collaborators

Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 8
Co-authored papers 7
Memorial Sloan Kettering Cancer Center.
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
St. Jude Children's Research Hospital
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Rutgers Cancer Institute of New Jersey, Rutgers University
Co-authored papers 2
Department of Pediatrics University of Minnesota Minneapolis MN.
Co-authored papers 2
Institute for Clinical and Translational Research, Baylor College of Medicine
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
University of Southern California
Co-authored papers 1
Center for Pharmacoepidemiology and Treatment Science, Rutgers University
Co-authored papers 1
Inc. San Carlos
Co-authored papers 1
Cancer Institute of New Jersey
Co-authored papers 1
University Medical Center Goettingen
Co-authored papers 1
Dana-Farber Cancer Institute
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
University of Southern California
Co-authored papers 1
The Institute of Cancer Research
Co-authored papers 1
Institute and Clinic for Occupational, University Hospital
Co-authored papers 1
Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham
Co-authored papers 1
University of Goettingen
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
University of Liverpool, Molecular & Clinical Cancer Medicine
Co-authored papers 1
Baylor College of Medicine
Co-authored papers 1
Flinders University Library, Flinders University
Co-authored papers 1